Lv31
210 积分 2024-03-15 加入
Impact of ionizable lipid type on the pharmacokinetics and biodistribution of mRNA-lipid nanoparticles after intravenous and subcutaneous injection
3小时前
已关闭
Safety Evaluation of Lipid Nanoparticle–Formulated Modified mRNA in the Sprague-Dawley Rat and Cynomolgus Monkey
3天前
已完结
RBC Membrane-coated Nanoparticles: A Comprehensive Review on the Preparation Methods, Characterisations and Applications
2个月前
已完结
Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial
3个月前
已完结
Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial
3个月前
已关闭
Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial
6个月前
已完结
Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989
6个月前
已完结
The Nonclinical Disposition and Pharmacokinetic/Pharmacodynamic Properties of N-Acetylgalactosamine–Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human
7个月前
已完结
Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of N-Acetylgalactosamine–Conjugated Small Interfering RNA Disposition and Gene Silencing in Preclinical Species and Humans
8个月前
已完结
Predicting Clinical Pharmacokinetics/Pharmacodynamics and Impact of Organ Impairment on siRNA‐Based Therapeutics Using a Mechanistic Physiologically‐Based Pharmacokinetic‐Pharmacodynamic Model
8个月前
已完结
皖公网安备34019202002308
